Literature DB >> 15472553

Role of different techniques for the placement of Denver peritoneovenous shunt (PVS) in malignant ascites.

Renzo Clara1, Dorico Righi, Massimiliano Bortolini, Silvia Cornaglia, Maria Antonella Ruffino, Claudio Zanon.   

Abstract

The aim of the study is to evaluate 3 different techniques of Denver peritoneovenous shunt (PVS) placement. Fifty-three patients with malignant ascites underwent placement of 55 Denver PVS by a surgical (33 cases) or percutaneous (18) or laparoscopically assisted (4) procedure. There were 2 cases of postoperative mortality due to cardiac failure, and 7 cases of shunt obstruction (2 of them required replacement). Twenty patients underwent subsequent palliative treatment with chemotherapy or surgery. Complication and control of ascites rates are similar for the 3 techniques. Placement of Denver PVS for the treatment of malignant ascites appears to be a safe and useful procedure. Surgical dissection of the jugular vein is not mandatory. The percutaneous technique is the easiest, fastest, and least invasive procedure. Laparoscopic-assisted positioning is recommended if a peritoneal biopsy and/or abdominal exploration is required for a definitive diagnosis.

Entities:  

Mesh:

Year:  2004        PMID: 15472553     DOI: 10.1097/01.sle.0000136675.54624.16

Source DB:  PubMed          Journal:  Surg Laparosc Endosc Percutan Tech        ISSN: 1530-4515            Impact factor:   1.719


  3 in total

1.  PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success.

Authors:  C R Tapping; L Ling; A Razack
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

Review 2.  Management of ascites.

Authors:  Fedja A Rochling; Rowen K Zetterman
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 3.  Symptomatic Fluid Drainage: Peritoneovenous Shunt Placement.

Authors:  Hooman Yarmohammadi; George I Getrajdman
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.